Real-world effectiveness of belimumab and anifrolumab in systemic lupus erythematosus: comparable trends in disease activity and glucocorticoid reduction
Despite the proven efficacy of belimumab and anifrolumab for SLE, their relative effectiveness remains uncertain owing to conflicting indirect comparison studies. We conducted a comparative effectiveness study using multicenter health records to evaluate the adjusted 12-month changes in the SLE Dise...
Saved in:
Main Authors: | Ryota Sato, Masaru Shimizu, Yuya Kondo, Kazushi Maruo, Yuki Kuroda, Hiroshi Ebe, Mizuki Yagishita, Naoto Umeda, Seiji Mogi, Ayako Ohyama, Ayako Kitada, Saori Abe, Hiromitsu Asashima, Haruka Miki, Hiroto Tsuboi, Isao Matsumoto |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-07-01
|
Series: | Immunological Medicine |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2025.2528296 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
EXPERIENCE WITH BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
by: E. A. Aseeva, et al.
Published: (2015-09-01) -
New possibilities for the treatment of systemic lupus erythematosus. How much does the effect cost?
by: E. A. Pyadushkina, et al.
Published: (2025-02-01) -
The role of anifrolumab in reshaping the treatment landscape of extra-renal systemic lupus erythematosus
by: Fulvia Ceccarelli, et al.
Published: (2025-07-01) -
Portrait of a patient with systemic lupus erythematosus for the prescription of the type I interferon inhibitor anifrolumab
by: T. M. Reshetnyak, et al.
Published: (2023-12-01) -
Position on the use of anifrolumab in patients with systemic lupus erythematosus with insufficient efficacy of standard therapy in real-life clinical practice. Comments from Russian experts
by: E. A. Aseeva, et al.
Published: (2024-06-01)